The expression of opticin in vitreous body and retina of diabetes mellitus rats

Hong Luo 1 , Xiaoping Qiu 1  and Yancheng Xu 1
  • 1 Department of ophthalmology, Zhongnan Hosipital, Wuhan University, Wuhan 430077, China

Abstract

Background: Diabetic retinopathy is a common complication of diabetes mellitus. Opcitin is a glycoprotein present in the vitreous body. Its role in diabetic retinopathy needs to be further defined.

Objective: Investigate and compare the mRNA and protein levels of opticin in vitreous body and retina in normal and diabetic rats.

Methods: Twenty-four male Sprague-Dawley (SD) rats were randomly divided into two groups (12/group), a streptozocin-induced diabetes (STZ) group and a control group. In the STZ group, 1% sterile STZ solution was injected into the rats intraperitonally (60mg/kg). An equal volume of sodium citrate buffer solution was administrated in the rats from the control group. The rats were sacrificed one month after various treatments. The eye bodies of three rats from each group were removed and fixed with 4% paraformaldehydeion for the following pathological analysis. Meanwhile, the vitreous bodies and retina of the other nine rats from each group were removed for the real-time PCR, immunohistochemistry, and western blot assays.

Results: The mRNA level of opticin in the vitreous body of diabetes mellitus (DM) rats was 5.66% of that of the control ones (p <0.01). The expression of opticin mRNA in retina of DM rats was 9.28% of that of the control ones (p <0.01). In addition, opticin protein was expressed in the vitreous body and retina of the normal rats, whereas it was negative in the DM ones.

Conclusions: The opticin expression in vitreous body and retina of diabetes rats was significantly decreased or even disappeared, which may suggest a key role of opticin in the development of diabetic retinopathy.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Reardon AJ, Le Goff M, Briggs MD, McLeod D, Sheehan JK, Thornton DJ, et al. Identification in vitreous and molecular cloning of opticin, a novel member of the family of leucine-rich repeat proteins of the extracellular matrix. J Biol Chem. 2000; 275:2123-9.

  • 2. Ramesh S, Bonshek RE, Bishop PN. Immunolocalisation of opticin in the human eye. Br J Ophthalmol. 2004; 88:697-702.

    • Crossref
    • Export Citation
  • 3. Hindson VJ, Gallagher JT, Halfter W, Bishop PN. Opticin binds to heparan and chondroitin sulfate proteoglycans. Invest Ophthalmol Vis sci. 2005; 46: 4417-23.

  • 4. Forrester JV. Shedding light on a new eye protein. Br J Ophthalmol. 2004; 88:602-3.

    • Crossref
    • Export Citation
  • 5. Le Goff MM, Slevin MA, Bishop PN. Opticin is an inhibitor of VEGF-A and FGF-2-activated angiogenesis. Invest Ophthalmol Vis Sci. 2005; 46:S451.

  • 6. Le Goff MM, Hindson VJ, Jowitt TA, Scott PG, Bishop PN. Characterization of opticin and evidence of stable dimerization in solution. J Biol Chem. 2003; 278: 45280-7.

  • 7. Friedman JS, Faucher M, Hiscott P, Biron VL, Malenfant M, Turcotte P, et al. Protein localization in the human eye and genetic screen of opticin. Hum Mol Genet. 2002; 11:1333-42.

    • Crossref
    • Export Citation
  • 8. Le Goff MM, Slevin MA, Bishop PN. Opticin is an inhibitor of VEGF-A and FGF-2-activated angiogenesis. Annual Invest Ophthalmol Vis Sci. 2005; 46:451.

  • 9. Sanders EJ, Walter MA, Parker E, Arámburo C, Harvey S. Opticin binds retinal growth hormone in the embryonoic vitreous. Invest Ophthalmol Vis Sci. 2003; 44:5404-9.

  • 10. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27: 283-90.

    • Crossref
    • Export Citation
  • 11. Hobby P, Wyatt MK, Gan W, Bernstein S, Tomarev S, Slingsby C, et al. Cloning , modeling , and chromosomal localization for a small leucine-rich repeat proteoglycan (SLRP) family member expressed in human eye. Mol Vis. 2000; 6:72-8.

  • 12. Sulochana KN, Fan H, Jois S, Subramanian V, Sun F, Kini RM, et al. Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis. J Biol Chem. 2005; 280:27935-48.

  • 13. Matthew JS, Magali LG, David W, Paul B, Mark S. Antiangiogenic properties of opticin. The FASEB Journal. 2007; 21:601.

  • 14. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 2005; 65:3967-79.

    • Crossref
    • Export Citation
  • 15. Sneddon SF, Telfer BA, Williams KJ, Bishop PN, Stratford IJ, Cowen RL. Opticin:a potent antiangiogenic/antiproliferative agent for breast cancer therapy. Breast Cancer Research. 2010; 12:53-63.

    • Crossref
    • Export Citation
  • 16. Pattwell DM, Sheridan CM, Le Goff M, Bishop PN, Hiscott P. Localisation of opticin in human proliferative retinal disease. Exp Eye Res. 2010; 90:461-4.

    • Crossref
    • Export Citation
OPEN ACCESS

Journal + Issues

Search